xperimental study for staging strategy establishment of schizophrenia
| Project/Area Number |
22591255
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
ABEKAWA Tomohiro 北海道大学, 大学院・医学研究科, 客員准教授 (80301901)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITAICHI Yuji 北海道大学, 大学院・医学研究科, 客員講師 (80374445)
伊藤 侯輝 北海道大学, 大学院・医学研究科, 助教 (40455663)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 統合失調症 / Staging strategy / 薬物療法 / 病態モデル / 実験研究 |
|---|
| Research Abstract |
In this study, we divided into the progress pathophysiology-stage and the subsequent residual-stage and examined the effects of second generation antipsychotics, mood stabilizers and medicine which stimulate NMDA receptor function in both stages and this research aimed at the establishment of suitable medication according to stages. From the results of this research, medicine which prevents the increases of extracellular glutamate concentration may have blocking effects in the progressive pathophysiology-stage and medicine which stimulate glutamatergic neurotransmission may recover in the subsequent residual-stage.
|
Report
(4 results)
Research Products
(21 results)
